The company has created an impressive patent portfolio with nearly 30 issued patents ranging from stent designs to surface coatings. The company has four clinical trials in process evaluating new materials and coatings. Data from the company's Moonlight Trial was presented at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in September. This trial set out to evaluate the impact of a proprietary passive stent coating, Iridium Oxide. At six-month follow up, the in-stent restenosis rate in this treatment group was less than 12 percent. This compares extremely favorably with the traditional restenosis rates of bare metal stents and may offer an attractive alternative for the segment of the international market that does not convert to a drug-eluting stent. While further studies will be required, Iridium Oxide may provide an attractive complement to Boston Scientific's drug-eluting stent program.

"We see the acquisition of InFlow providing us with an expanded technology portfolio," said Fred Colen, Chief Technology Officer of Boston Scientific. "Dr. Alt and the team he's assembled have done some very compelling work that we will immediately blend with our internal product development process."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, regulatory approvals, intellectual property, competitive offerings, integration of acquired companies, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.